Extended-interval tarlatamab dosing shows consistent efficacy and safety in previously treated small cell lung cancer
Source Summary
The Phase II DeLLphi-309 randomized trial found that extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety, and pharmacokinetic profiles consistent with the established every-two-week dosing schedule in patients with previously treated small cell lung cancer. Results were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer.
Why it matters
Extended-interval dosing could improve treatment convenience and patient compliance by reducing the frequency of tarlatamab administration while maintaining therapeutic benefit in small cell lung cancer patients.
